Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis
<b>Objective:</b> The course of relapsing–remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/40 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589047791353856 |
|---|---|
| author | Işıl Peker Hacer Eroğlu İçli Belgin Mutluay Burcu Yüksel Zeynep Özdemir Mesrure Köseoğlu Aysu Şen Dilek Ataklı Aysun Soysal Musa Öztürk |
| author_facet | Işıl Peker Hacer Eroğlu İçli Belgin Mutluay Burcu Yüksel Zeynep Özdemir Mesrure Köseoğlu Aysu Şen Dilek Ataklı Aysun Soysal Musa Öztürk |
| author_sort | Işıl Peker |
| collection | DOAJ |
| description | <b>Objective:</b> The course of relapsing–remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (CCL11), and macrophage inflammatory protein 3-alpha (CCL20) in RRMS. <b>Methods:</b> Forty-two patients with MS were enrolled, along with 22 controls, 12 of the controls were idiopathic intracranial hypertension (IIH) patients, and 10 of the controls were other neurologic diseases (OND). Chemokine levels were measured using enzyme-linked immunosorbent assay (ELISA) in serum and cerebrospinal fluid (CSF) samples. <b>Results:</b> No significant differences were observed among the groups in serum levels of CXCL13, CCL11, and CCL20 (<i>p</i> = 0.509, <i>p</i> = 0.979, <i>p</i> = 0.169, respectively). CSF CXCL13 levels were significantly higher in the OND group (<i>p</i> = 0.016). A PATH analysis showed CSF CXCL13 was significantly associated with new T2 hyperintense lesions on brain magnetic resonance imaging (<i>p</i> < 0.001), and baseline serum CCL11 levels were associated with EDSS (<i>p</i> = 0.030), implying its potential role in indicating neurodegenerative processes and possible progression risk. Serum CCL20 correlated with EDSS (<i>p</i> = 0.002) and lesion burden (<i>p</i> < 0.001), reflecting disease severity. <b>Conclusions:</b> These findings suggest that CSF CXCL13 could serve as a useful biomarker for predicting active disease in RRMS, while follow-up serum CCL11 may assist in identifying progression. Although these chemokines are not specific to MS, higher levels may signal disease activity, severity, and transition to more progressive stages. |
| format | Article |
| id | doaj-art-67bed3f4292e4e9e80a8fb0ba24cfad7 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-67bed3f4292e4e9e80a8fb0ba24cfad72025-01-24T13:23:48ZengMDPI AGBiomedicines2227-90592024-12-011314010.3390/biomedicines13010040Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple SclerosisIşıl Peker0Hacer Eroğlu İçli1Belgin Mutluay2Burcu Yüksel3Zeynep Özdemir4Mesrure Köseoğlu5Aysu Şen6Dilek Ataklı7Aysun Soysal8Musa Öztürk9Department of Neurology, Edirne Sultan 1. Murat State Hospital, 22030 Edirne, TurkeyDepartment of Biochemistry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Kanuni Sultan Suleiman Research and Training Hospital, 34303 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, TurkeyDepartment of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, Turkey<b>Objective:</b> The course of relapsing–remitting multiple sclerosis (RRMS) is highly variable and there is a lack of effective prognostic biomarkers. This study aimed to assess the potential prognostic value of the chemokines B lymphocyte chemoattractant molecule (CXCL13), eotaxin-1 (CCL11), and macrophage inflammatory protein 3-alpha (CCL20) in RRMS. <b>Methods:</b> Forty-two patients with MS were enrolled, along with 22 controls, 12 of the controls were idiopathic intracranial hypertension (IIH) patients, and 10 of the controls were other neurologic diseases (OND). Chemokine levels were measured using enzyme-linked immunosorbent assay (ELISA) in serum and cerebrospinal fluid (CSF) samples. <b>Results:</b> No significant differences were observed among the groups in serum levels of CXCL13, CCL11, and CCL20 (<i>p</i> = 0.509, <i>p</i> = 0.979, <i>p</i> = 0.169, respectively). CSF CXCL13 levels were significantly higher in the OND group (<i>p</i> = 0.016). A PATH analysis showed CSF CXCL13 was significantly associated with new T2 hyperintense lesions on brain magnetic resonance imaging (<i>p</i> < 0.001), and baseline serum CCL11 levels were associated with EDSS (<i>p</i> = 0.030), implying its potential role in indicating neurodegenerative processes and possible progression risk. Serum CCL20 correlated with EDSS (<i>p</i> = 0.002) and lesion burden (<i>p</i> < 0.001), reflecting disease severity. <b>Conclusions:</b> These findings suggest that CSF CXCL13 could serve as a useful biomarker for predicting active disease in RRMS, while follow-up serum CCL11 may assist in identifying progression. Although these chemokines are not specific to MS, higher levels may signal disease activity, severity, and transition to more progressive stages.https://www.mdpi.com/2227-9059/13/1/40relapsing–remitting multiple sclerosisB lymphocyte chemoattractant moleculeeotaxin-1macrophage inflammatory protein 3-alfabiomarkers |
| spellingShingle | Işıl Peker Hacer Eroğlu İçli Belgin Mutluay Burcu Yüksel Zeynep Özdemir Mesrure Köseoğlu Aysu Şen Dilek Ataklı Aysun Soysal Musa Öztürk Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis Biomedicines relapsing–remitting multiple sclerosis B lymphocyte chemoattractant molecule eotaxin-1 macrophage inflammatory protein 3-alfa biomarkers |
| title | Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis |
| title_full | Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis |
| title_fullStr | Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis |
| title_full_unstemmed | Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis |
| title_short | Prognostic Value of CXCL13, CCL11, and CCL20 Chemokines in Multiple Sclerosis |
| title_sort | prognostic value of cxcl13 ccl11 and ccl20 chemokines in multiple sclerosis |
| topic | relapsing–remitting multiple sclerosis B lymphocyte chemoattractant molecule eotaxin-1 macrophage inflammatory protein 3-alfa biomarkers |
| url | https://www.mdpi.com/2227-9059/13/1/40 |
| work_keys_str_mv | AT isılpeker prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT hacererogluicli prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT belginmutluay prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT burcuyuksel prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT zeynepozdemir prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT mesrurekoseoglu prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT aysusen prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT dilekataklı prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT aysunsoysal prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis AT musaozturk prognosticvalueofcxcl13ccl11andccl20chemokinesinmultiplesclerosis |